JAK2 V617F MUTATION AND PRV-1 OVEREXPRESSION: RELEVANCE IN THE DIAGNOSIS OF POLYCYTHAEMIA VERA AND ESSENTIAL THROMBOCYTHAEMIA

REFERENCES

• Chronic myeLoproLiferative diseases In: Jaffe ES, Harris NL, Stein H, Vardiman LW, eds. WHO CLassification of Tumours: Pathok ogy and genetics of tumours of the Hematopoietic and Lym-phoid Tissues. IARC Press Lyon 2001: p15–44.
   Google Scholar
• NoweLL PC, Hungerford DA. A minutre chromosome in human chronic granu Locytic Leukemia. Science 1960; 132: 1497–1500.
   Web of Science ®Google Scholar
• Temerinac S, KLippeL S, Strunck E, et al CLoning of PRV-1, a noveE member of the uPAR receptor superfamiLy, which is over-expressed in poLycythemia rubra vera. Blood 2000; 95: 2569–2576.
   PubMed Web of Science ®Google Scholar
• Liu E, JeLinek J, Pastore YD, Guan Y, PrchaL JF, PrchaL JT. Discrimi-nation of poLycythemias and thrombocytoses by noveL simpLe accurate donaLity assays and comparison with PRV-1 expres-sion and BFU-E response to erythropoietin. Blood 2003; 101: 3294–3301.
   PubMed Web of Science ®Google Scholar
• KraLovics R, Buser AS, Teo SS, et al Comparison of moLecuLar markers in a cohort of patients with chronic myeLoproLiferative disorders. Blood 2003; 102: 1869–1871.
   PubMed Web of Science ®Google Scholar
• KlippeL S, Strunck E, Temerinac S, et al Quantification of PRV-1 mRNA distinguishes poiycythemia vera from secondary eryth-rocytosis. Blood 2003; 102: 3569–3574.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, WoLanskyj AP, Mesas RA. NeutrophiL PRV-1 expression across the chronic myeLoproLiferative disorders and in secondary or spurious poLycythemia. Blood 2004;103:3547–3548.
   PubMed Web of Science ®Google Scholar
• Florensa L, Besses C, Zamora L, et al , Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonal-ity assay, and PRV-1 expression are usefuL took for diagnosis of poLycythemia vera and essentiaL thrombocythemia. Blood 2004; 103:2427–28.
   Web of Science ®Google Scholar
• TeofiLi L, Martini M, Luongo L et al, Overexpression of the poLy-cythemia ru bra vera-1 gene in essentiaL thrombocytemiaj Clin Oncol 2002; 20: 4249–4254.
   Web of Science ®Google Scholar
• Sirhan S, Lasho TL, Eliot MA, Tefferi A, NeutrophiL poLycythemia ru bra vera-1 expression in dassic and atypicaL myeLoproLifera-tive disorders and Laboratory correLates. Haematologica 2005; 90:406–408.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Pietra D, Makbarbra L et al, CLinicaL significance of neutrophiL CD177 mRNA expression in Ph-negative chronic myeLoproLiferative disorders. Br] Haematol 2004; 126: 650–6.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Sirhan S, Lasho TL et al, Concomitant neutrophiL JAK2 V617F mutation screening and PRV-1 expression anaLysis in myeLoproLiferative disorders and secondary poLycythaemia, Br ]Haematol 2005; 131: 166–171.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, CampLbeLL PJ, et al Acquired mutation of the tyrosine kinase JAK2 in human myeLoproLiferative disor-ders. Lancet 2005; 365: 1054–1061.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al A unique donaL JAK2 mu-tation Leading to constitutive signaling causes poLycythaemia vera. Nature 2005;434: 1144–1148.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al A gain of function mutation in JAK2 is frequentLy found in patients with myeLo-proLiferative disorders. N Eng J Med 2005; 352: 1779–1790.
   PubMed Web of Science ®Google Scholar
• Levine RL, Waclleigh M, Cook J, et al Activating mutation in the tyrosine kinase JAK2 in poLycythemia vera, essentiaL thrombo-cytemia, and myeLoid metapLasia with myeLofibrosis. Cancer Cell 2005; 7: 387–397.
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z, et al , Identification of an acquired JAK2 mutation in poLycythemia vera.] Biol Chem 2005;280: 22788–22792.
   PubMed Web of Science ®Google Scholar
• Jones AV, KreiL S, Zoi K, et al Widespread occurrence of the JAK2 V617F mutation in chronic myeLoproLiferative disorders. Blood 2005; 15:2162–2168.
   Web of Science ®Google Scholar
• Tefferi A, Sirhan S, Lasho TL, et al Concomitant neutrophiL JAK2V617F mutation screening and PRV-1 expression anaLysis in myeLoproLiferative disorders and secondary poLycythemia. Br ]Haematol 2005;13: 166–171.
   Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McCLure RF, et al JAK2V617F-mutation in essentiaL thromocythaemia; cLinicaL associations and Long-term prognostic reLevance. Br] Haematol 2005;131: 208–213.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. CLassification and diagnosis of myeLo-proLiferative neopLasms:TheWorLd HeaLth Organization criteria and point-of-care diagnostic aLgorithms. Leukemia 2008;22;14–22.
   PubMed Web of Science ®Google Scholar